NanoViricides Inc. (NNVC)

[Ubertino]

Full speed ahead

"Successful testing of our drug candidates in animal models of the dermal, ocular, and genital herpesvirus diseases at the University of Wisconsin would enable us to rapidly move these drug candidates towards human clinical trials," said Dr. Anil R. Diwan, President and Chairman of the Company, adding, "This will further bolster our pipeline and increase the total value of our HerpeCide assets several-fold, with minimal additional investments. The expansion of our agreement with the CORL at University of Wisconsin is thus very significant for creating substantially increased business value."